HOWARD COUNTY BEHAVIORAL HEALTH PROVIDER COVID-19 RESOURCE & RESPONSE CALL #4

April 15, 2020





@hclhic 🔽 🚹

@hclhic 🔽 🛭

1

Participants will be muted upon entry. Using the icons on your screen, you can: Mute/Unmute your microphone; Mute/Unmute button on phone Please mute yourself during discussion/questions if not speaking Use the "chat" feature to ask questions during the presentation. View Participant list on computer—opens a pop-out screen that includes a "Chat" icon that you may use to submit questions Question/ comment can also be added to the chat box throughout the meeting Not a Video Call...you cannot see us and we cannot see you...we can only hear you.

www.hclhic.org


2


Promote. Preserve. Protect.

Roe Rodgers-Bonaccorsy Director, Bureau of Behavioral Health Howard County Health Department

www.hclhic.org

GOAL: Learn how Medication Assisted Treatment (MAT) providers are serving clients during the COVID-19 pandemic. OBJECTIVES: 1. Welcome & opening remarks 2. Kolmac Clinic 3. Silverman Treatment Solutions 4. Q&A 5. Closing remarks





George Kolodner, MD



George Kolodner, MD, is the designer of the first intensive outpatient addiction treatment program in the country. For over 40 years, he has served the people of the Maryland and D.C. area.

and D.C. area.

Dr. Kolodner specializes in the ambulatory treatment of substance use disorders. Currently, he serves as the Medical Director and Chief Innovation Officer for Kolmac Outpatient Recovery Centers. Their outpatient services include detoxification, medication-assisted treatment (MAT), rehabilitation, and continuing care for patients with and without other co-occurring psychiatric disorders. In addition to his work at Kolmac, Dr. Kolodner serves as a Clinical Professor of Psychiatry at both the University of Medicine and Georgetown University. He was the Lead Author of the Withdrawal Management chapter of The ASAM Criteria.

Dr. Kolodner has a Medical Degree from the University of Rochester and completed his psychiatry residency at Yale

7

Outpatient Withdrawal Management

Outpatient Detox/Withdrawal Management is a difficult to find service in many markets
Despite being a well-established procedure for mild to moderate severity
Articles: 1975, American Journal of Psychiatry. 1989, New England Journal of Medicine

American Society of Addiction Medicine (ASAM) Criteria Outpatient WM Treatment Levels
Level 1-WM: Ambulatory Withdrawal Management without Extended On-Site Monitoring
Level 2-WM: Ambulatory Withdrawal management with Extended On-Site Monitoring
Use front-loaded, symptom-triggered protocols to stabilize patients in first 2 to 4 hours

- Alcohol: most dangerous withdrawal syndrome
 Opioids: use of buprenorphine for heroin withdrawal complicated by fentanyl
 Use of 48 hour "tramadol bridge"
 Benzodiazepines: need for 4 to 8 week taper

8

ASAM Criteria Risk Rating Scale to Determine Treatment Setting

to Determine Treatment Setting					
Risk Rating	Symptoms Level of Co				
1. Mild	Mild anxiety, sweating, insomnia	WM-1 WM-2			
2. Moderate	Moderate anxiety, fine tremor	WM-2			
3. Significant	Significant anxiety, gross tremor	WM-2 Residential			
4. Severe	Clouded sensorium, visual hallucinations, seizure	Hospital			

Key Modifications for Virtual Withdrawal Management

- Screen out complex patients
 Alcohol: history of withdrawal seizures or visual hallucinations
- Behavioral: unreliable behavior or insufficiently committed to entire process
 Require mandatory participation in IOP as soon as withdrawal symptoms are tolerable.
- Require involvement of reliable medication manager
 Have direct communication with manager who holds and dispenses medication as instructed by medical clinician
 - Address pressuring of manager by patient for more medication
- Provide written instructions
 Medication issues

- Larger doses necessary
 Full comfort is more difficult to achieve
- Problematic issues
 Unfamiliarity of pharmacists with aggressive medication protocols ("Six a day is too much.")

 "Six a day is too much."
 - Difficulty obtaining urine toxicology and breathanalysis

10

Outcomes: First Four Weeks

• Total patients: 37

• Transitioned to ongoing treatment: 33



SILVERMAN TREATMENT SOLUTIONS				
Teron Powell, MS				
Executive Director Silverman Treatment Solutions				
Promote. Preserve. Protect.	www.hclhic.org	@hclhic 🗾 f		



COVID-19 has dramatically impacted the treatment landscape as we know it.

 Opioid Treatment Providers (OTP) and Medication Assisted Treatment/Therapies (MAT) tacilities are medically essential for treating the state's 30,000+ enrolled patients.

OTP & MAT DURING COVID-19

0.51.00.000.00		
 On February 28, 2020 Silverman Treatment Solutions (STS) posted its first on many COVID-19 advisories informing its staff, patients, 		
and stakeholders of precautionary steps taken in order to prepare for a potential outbreak.	•	
 STS, just like many other providers, scrambled to draft new policies and procedures in order to address the nature of 		
COVID-19 as we understood it at the time.	•	
 On March, 16, 2020 our organization adopted the before mentioned policies as we continues treatment operations. 		
OTP & MAT DURING COVID-19		
	/	
16		
To undersome the page of change that was is a coursing its		
 To underscore the pace of change that was/is occurring, its important to note that OTP/MAT and other behavioral health 		
providers began receiving official (BHA, SAMHSA, DEA) guidance about COVID-19 on March 2, 2020.		
 This was of course followed by many iterations of COVID-19 FAQs, health tips/precautions, PPE, and other advisories 		
 On March 16, 2020 STS coordinated with HCHD to acquire 150 		
Narcan kits for patients. STS subsequently acquired 200 additional kits to account for 100% of its patient population.	-	
OTP & MAT DURING COVID-19		
	,	
17		
 On March 15, 2020 BHA urged clinics like STS to increase the storage of methadone onsite. 		
One day later BHA, through SAMHSA, called for blanket		
exceptions for the entire state 14-28 days. > "Exceptions" through the SAMHSA extranet site are typically a		
mechanism for OTPs to request additional doses of medication		
or "take homes" for its patients. Generally request are guided by strict adherence criteria (Drug screens, time in treatment, clinical		
engagement, etc.) that warrant extra meds for a few days or week.	-	
On March 18, 2020 STS formally submitted it blanket exception		
request to the BHA and SAMHSA.		

18

OTP & MAT DURING COVID-19

Blanket exceptions for dosing at 5T3:

In response to the COVID-19 outbreak, STS has implemented the following measures regarding doing and take-home medications:

\$TS has begue insiting the amount of parlies that will be allowed into the clinic at one time. Each patient is encouraged to call ahead of time for check-in while remaining in their cars. AMS as an organization has worked with their healthyles (Affendance) for activate a mobile of page 10 on a silver mobile of their healthyles (Affendance) to activate a mobile opposition of their page 10 on a silver mobile of their healthyles (Affendance) and that y crofiles will register in the que for patients of their page 10 on their force and that y crofiles will register in the que for medication dispensing. This will allow client to remain in their cars, nutries to prepare dozes, and decrease physical traffic inside of the clinic.

Patients who are entering the lobby must sit every other seat. Dozoways are open to decrease the amount of Touch points' encountered stTs has also moved quickly to instalt if features to advance opportunities for felemeticinn (Tele seasons to regularly occur.)

It is an internal policy for all apients and staft to be trained and equipped with Narcan kits. Although mandated as an 155 policy, every patient receiving take home medications regardless of Phase in treatment will receive an additional Narcan kit. Narcan kits remain free and available on-site at 1515.

OTP & MAT DURING COVID-19

19

Phases and Doses

1. Patients with the program status of Phase 0-3 are being provided 7 days of take home medications. All patients are staggered throughout the week as to not overwhelm the dispensary or crowd the lobby area.

2. Patients phase 57- Will remain at their program status and report on their assigned days for the assigned amounts of medications for the Phase they possess.

1. Patients who have illicit use to the degree it is determined to be clinically unstable; medically unable (ex. Dialysis patients); new intakes to treatment will be medicated daily, all will be monitored evaluated constantly as we move through this process.

4. Any patients who wishes to continue to dose daily for personal reasons (daily recovery routine, environmenta), etc.) will also be permitted to do so. However; they will be encourage to call ahead for clinic check-in to be dosed "curbside".

Recognizing this current crisis is a dynamic and fluid scenario, STS continues to stay informed and proactive in terms of treating patients and staff. it is our sincerest goal to ensure all patients and staff receive the safest care we can deliver as we continue to learn more about COVID-19.

OTP & MAT DURING COVID-19

20

Promote. Preserve. Protect.

Please use the Chat Box to submit questions!

Presentations and recording will be posted at www.hclhic.org

For additional information or questions contact hic@howardcountymd.gov

CLOSING REMARKS Upcoming Calls: Friday 4/24/2020 from 9:00 AM – 10:30 AM Presentations, recording, & additional resources will be posted at www.hclhic.org For additional information, contact lhic@howardcountymd.gov For questions related to COVID-19 supplies: www.surveymonkey.com/r/Q7MPHNM For general questions related to COVID-19, e-mail askhealth@howardcountymd.gov

www.hclhic.org

@hclhic 💆 f

22

